Recognising that the access to and affordability of medicines is one of the biggest challenges for people living with HIV in WHO Europe, the EAG operates a comprehensive portfolio on related questions and topics. Webinars are organised to inform members of the HIV/AIDS and related co-infections communities and patient advocates beyond these areas. Position papers and educational materials facilitate the involvement of civil society in changing the landscape of intellectual property rights, the methodologies and economic models of medicines development, and – as the main objective – access to affordable and quality medicines to all who need them.
Overall aim: to tackle the challenges concerning access to and affordability of medicines and to facilitate the involvement of civil society in the policy and advocacy around topics that influence the availability of affordable medicines for all who need them, such as registration, pricing, procurements, intellectual property issues, trade-related agreements and others.
- To inform the EATG membership and partners about issues related to sustainable universal access to treatment and to affordable state of the art medicines for HIV, TB and HCV;
- To facilitate the involvement of civil society in changing the landscape of intellectual property rights as well as the methodologies and economic models of medicines development.
- Organisation of webinars to inform members of the HIV/AIDS and related co-infections communities and patient advocates beyond these areas;
- Producing of position papers and educational materials to enhance the involvement of civil society.
- The EATG members and partners are informed of issues related to access and affordability of medicines and diagnostics;
- The EATG will contribute to achieving access to affordable and quality medicines to all who need them.
The following pages provide more information on the outcomes and products of the policy and advocacy work in this field.
Read the Position Paper on ensuring affordable anti-retroviral drugs, sustainable universal access to treatment, as well as continued innovation in research and development (2012) here: EATG Position Paper on Access and Innovation FINAL 201210
Read the Call to EU Ministers of Health and CEOs of Abbvie, BMS, Gilead, Janssen and Merck/MSD regarding Universal Access to Curative Hepatitis C Treatment in the EU and Beyond (2014) here: Call on European Union governments and pharmaceutical industry hepatitis C (1)
Read the Sitges VII Declaration on accessible and affordable treatment to HCV medication for all people who need it: Sitges VII Declaration(4)
For more information contact EATG Policy Officer Ann-Isabelle von Lingen on: email@example.com
Webinar – Affordability and Access to Medicines (April 2016)
Case study on access to DAAs in Portugal (December 2016)